Three posters on the anti-KIR program to be presented at the upcoming ASH annual meeting
Launch of IND-Enabling studies for IPH4102
Innate Pharma announces revenue for the first nine months of 2013 and updates on its cash position
Innate Pharma presents proprietary antibody-drug conjugate technology at the World ADC Summit in San Francisco
Innate Pharma appoints Nicolai Wagtmann Chief Scientific Officer
Financial results for the first half of 2013
Innate Pharma announces first DSMB review of ongoing EffiKIR Phase II trial with lirilumab
Half-year report on Innate Pharma’s liquidity contract with Gilbert Dupont
Annual General Meeting of June 28, 2013
Number of shares and voting rights of Innate Pharma as at May 17, 2013
